Vitamin D Supplementation in Bifosfonate Therapy

Introduction to Bifosfonate Therapy

The American College of Rheumatology recommends that vitamin D deficiency should be corrected before starting bifosfonate therapy, especially for intravenous formulations 3, 4
Vitamin D deficiency can completely attenuate the efficacy of bifosfonates, leading to continuous loss of bone mineral density (BMD) despite treatment 1, 2

The American College of Rheumatology states that uncorrected vitamin D deficiency is an absolute contraindication to starting intravenous bifosfonate therapy 3, 4
The risk of hypocalcemia is particularly high with intravenous formulations (zoledronic acid, pamidronate) compared to oral formulations 1, 5
Hypocalcemia can be asymptomatic and transient in most cases, but can become clinically significant in the presence of pre-existing vitamin deficiency 6

The goal is to achieve 25-OHD levels >32 ng/mL, although some experts recommend 40-50 ng/mL 1, 2
For moderate deficiencies (25-OHD >15 ng/mL), vitamin D3 2000 UI/day for 12 weeks, then 1000-2000 UI/day for maintenance 1, 2
For severe deficiencies (25-OHD <15 ng/mL) with secondary hyperparathyroidism, vitamin D2 50,000 UI/week for 8-12 weeks, then monthly 1, 2

Before starting therapy, measure 25-OHD, serum calcium, creatinine, phosphorus, and magnesium levels 6, 4
Documented correction of deficiency before starting intravenous bifosfonates 1, 3
Regular monitoring of serum calcium, phosphorus, and magnesium levels during therapy, as hypocalcemia and hypophosphatemia have been reported 6, 4

Never start intravenous bifosfonates without first verifying and correcting vitamin D status 3, 4
Each 40 UI increase in vitamin D3 increases 25-OHD by 0.4 ng/mL, allowing for personalized dosage calculations 1, 2